Strata Skin Sciences Inc.
| NASDAQ: SSKN | Healthcare / Medical Devices & Instruments / USA |
| 1.16 | +0.0100 | +0.87% | Vol 29.88K | 1Y Perf -17.27% |
| Feb 6th, 2023 16:00 DELAYED |
| BID | 1.07 | ASK | 1.15 | ||
| Open | 1.15 | Previous Close | 1.15 | ||
| Pre-Market | - | After-Market | 1.11 | ||
| - - | -0.05 -4.31% |
| Target Price | 3.30 | Analyst Rating | Strong Buy 1.00 | |
| Potential % | 184.48 | Finscreener Ranking | ★★★★+ 57.32 | |
| Insiders Trans % 3/6/12 mo. | 100/100/100 | Value Ranking | ★★ 47.66 | |
| Insiders Value % 3/6/12 mo. | 100/100/100 | Growth Ranking | ★+ 40.54 | |
| Insiders Shares Cnt. % 3/6/12 mo. | 100/100/100 | Income Ranking | — - | |
| Price Range Ratio 52W % | 38.89 | Earnings Rating | Strong Buy | |
| Market Cap | 40.28M | Earnings Date | 20th Mar 2023 | |
| Alpha | -0.02 | Standard Deviation | 0.18 | |
| Beta | 1.90 |
Today's Price Range 1.121.25 | 52W Range 0.74001.82 | 5 Year PE Ratio Range -10.00-1.60 |
Summary:
Buy
| Technical Indicators: | Neutral |
| Moving Averages: | Strong Buy |
| Performance | |||
|---|---|---|---|
| 1 Week | 26.09% | ||
| 1 Month | 41.46% | ||
| 3 Months | 29.94% | ||
| 6 Months | 10.48% | ||
| 1 Year | -17.27% | ||
| 3 Years | -36.26% | ||
| 5 Years | -13.43% | ||
| 10 Years | -98.62% |
| Mngmt Effectiveness | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
ROE (5Y Avg) | -8.46 | |||
ROE last 12 Months | -28.37 | |||
ROA (5Y Avg) | -4.22 | |||
ROA last 12 Months | -13.44 | |||
ROC (5Y Avg) | -10.74 | |||
ROC last 12 Months | -17.85 | |||
Return on invested Capital Q | -2.60 | |||
Return on invested Capital Y | -2.51 | |||
Assets Turnover | 0.50 | |||
Receivables Turnover | 7.70 |
| Valuation | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| -4.60 | ||||
| 1.31 | ||||
| 1.10 | ||||
| 41.90 | ||||
| -7.60 | ||||
| -0.01 | ||||
| -5.57 | ||||
| 0.63 | ||||
| 29.37M | ||||
| Forward PE | -10.45 | |||
| PEG | - |
| Financial Strength | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 0.80 | ||||
| 1.30 | ||||
| 0.27 | ||||
| 0.38 | ||||
| -6.30 | ||||
| Leverage Ratio | 2.40 |
| Profitability | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 60.40 | ||||
| -15.50 | ||||
| 0.00 | ||||
| -22.70 | ||||
| -21.08 |
| Revenue | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| 25.56M | ||||
| 0.74 | ||||
| -2.08 | ||||
| -2.43 |
| Dividends | Value | Industry | S&P 500 | US Markets |
|---|---|---|---|---|
| - | ||||
| - | ||||
| - | ||||
| - | ||||
| Payout ratio | - |
| Earnings History | Estimate | Reported | Surprise % |
|---|---|---|---|
| Q03 2022 | -0.06 | -0.03 | 50.00 |
| Q02 2022 | -0.04 | -0.05 | -25.00 |
| Q01 2022 | -0.05 | -0.07 | -40.00 |
| Q04 2021 | -0.03 | -0.02 | 33.33 |
| Q03 2021 | -0.04 | -0.02 | 50.00 |
| Q02 2021 | -0.06 | -0.03 | 50.00 |
| Q01 2021 | -0.03 | -0.07 | -133.33 |
| Q04 2020 | -0.02 | -0.01 | 50.00 |
| Earnings Per End | Estimate | Revision % | Trend |
|---|---|---|---|
| 12/2022 QR | -0.04 | 0.00 | - |
| 12/2022 FY | -0.20 | 13.04 | Positive |
| 3/2023 QR | -0.04 | 0.00 | - |
| 12/2023 FY | -0.11 | 8.33 | Positive |
| Next Report Date | 20th Mar 2023 |
| Estimated EPS Next Report | -0.04 |
| Estimates Count | 1 |
| EPS Growth Next 5 Years % | - |
| Volume Overview | |
|---|---|
| Volume | 29.88K |
| Shares Outstanding | 34.72K |
| Shares Float | 17.98M |
| Trades Count | 143 |
| Dollar Volume | 35.16K |
| Avg. Volume | 28.00K |
| Avg. Weekly Volume | 53.70K |
| Avg. Monthly Volume | 18.23K |
| Avg. Quarterly Volume | 12.06K |
Strata Skin Sciences Inc. (NASDAQ: SSKN) stock closed at 1.16 per share at the end of the most recent trading day (a 0.87% change compared to the prior day closing price) with a volume of 29.88K shares and market capitalization of 40.28M. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Medical Devices & Instruments industry, Healthcare sector and employs 115 people. Strata Skin Sciences Inc. CEO is Dolev Rafaeli.
The one-year performance of Strata Skin Sciences Inc. stock is -17.27%, while year-to-date (YTD) performance is 46.82%. SSKN stock has a five-year performance of -13.43%. Its 52-week range is between 0.74 and 1.82, which gives SSKN stock a 52-week price range ratio of 38.89%
Strata Skin Sciences Inc. currently has a PE ratio of -4.60, a price-to-book (PB) ratio of 1.31, a price-to-sale (PS) ratio of 1.10, a price to cashflow ratio of 41.90, a PEG ratio of 2.32, a ROA of -13.44%, a ROC of -17.85% and a ROE of -28.37%. The company’s profit margin is -21.08%, its EBITDA margin is 0.00%, and its revenue ttm is $25.56 Million , which makes it $0.74 revenue per share.
Of the last four earnings reports from Strata Skin Sciences Inc., there were 2 positive earnings surprise and 2 negative earnings surprise. The company has EPS estimate of $-0.04 for the next earnings report. Strata Skin Sciences Inc.’s next earnings report date is 20th Mar 2023.
The consensus rating of Wall Street analysts for Strata Skin Sciences Inc. is Strong Buy (1), with a target price of $3.3, which is +184.48% compared to the current price. The earnings rating for Strata Skin Sciences Inc. stock is Strong Buy (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Strata Skin Sciences Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Strata Skin Sciences Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 22.11, ATR14 : 0.07, CCI20 : 360.26, Chaikin Money Flow : -0.33, MACD : 0.04, Money Flow Index : 89.01, ROC : 30.68, RSI : 79.20, STOCH (14,3) : 65.22, STOCH RSI : 1.00, UO : 48.72, Williams %R : -34.78), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Strata Skin Sciences Inc. in the last 12-months were: Christopher Lesovitz (Buy at a value of $25 907), Robert Joseph Moccia (Buy at a value of $52 398), Shmuel Rubinstein (Buy at a value of $1 092), William D. Humphries (Buy at a value of $52 771)
Strata Skin Sciences Inc.
Strata Skin Sciences Inc is a medical technology company engaged in developing and commercializing products for the treatment of dermatological disorders. The company's operating segment include Dermatology Recurring Procedures and Dermatology Procedures Equipment. It generates maximum revenue from the Dermatology Recurring Procedures segment. The Dermatology Recurring Procedures segment derives its revenues from the usage of its equipment by dermatologists to perform XTRAC procedures. Its Dermatology Procedures Equipment segment generates revenues from the sale of equipment, such as lasers and lamp products. Geographically, it derives a majority of revenue from the United States.
CEO: Dolev Rafaeli
Telephone: +1 215 619-3200
Address: 5 Walnut Grove Drive, Horsham 19044, PA, US
Number of employees: 115
